Literature DB >> 30367375

Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital.

Jean-Pierre Jourdan1,2, Alexandra Muzard3, Isabelle Goyer3, Yann Ollivier4, Youssef Oulkhouir5, Patrick Henri6, Jean-Jacques Parienti7, Cécile Breuil3.   

Abstract

Background A significant number of clinical pharmacy services have shown to improve in-hospital medication safety and patient outcome. Prescription review and pharmacist interventions are a fundamental part of hospital clinical pharmacy activities. In a context of restricted financial resources, proving the economic and clinical impact of this activity seems necessary. Objective The aim of this study was to assess the clinical impact on patient outcomes and economic benefit of prescription review by pharmacists. Setting 1624-bed tertiary French university teaching hospital. Method Prospective single center study evaluating prescriptions for which a pharmacist intervention was issued over a 6-month period. The clinical impact of every pharmacist intervention was evaluated by a multidisciplinary experts committee. Economic benefit was evaluated from the public health care system spending standpoint. Main outcome measures Number of avoided hospitalization days and associated public health care system cost-avoidance. Results Prescription review and interventions by pharmacists prevented 73 intensive care unit hospitalization days, 74 continuous monitoring unit hospitalization days and 66 days of conventional hospitalization. €252,294.00 in public health expenditure were thus prevented. For every Euro invested in the prescription review activity, €5.09 of public health spending were potentially saved. Conclusion Our study shows that prescription review and clinical pharmacists' interventions had an impact on clinical outcomes which translated into prevented hospitalization days. Prescription optimization through pharmacist interventions allows significant health care cost savings which makes this service highly efficient.

Entities:  

Keywords:  Clinical pharmacy services; France; Health care costs; Pharmacist Interventions; Presciption review

Mesh:

Year:  2018        PMID: 30367375     DOI: 10.1007/s11096-018-0733-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  6 in total

1.  A cost-benefit analysis of hospital-wide medication reviews: a period prevalence study.

Authors:  Sarah Wilkes; Rianne J Zaal; Alan Abdulla; Nicole G M Hunfeld
Journal:  Int J Clin Pharm       Date:  2021-09-08

2.  Clinical pharmacists' interventions across German hospitals: results from a repetitive cross-sectional study.

Authors:  Claudia Langebrake; Carina Hohmann; Susanne Lezius; Michael Lueb; Gesine Picksak; Wencke Walter; Sandra Kaden; Heike Hilgarth; Angela Ihbe-Heffinger; Katja Leichenberg
Journal:  Int J Clin Pharm       Date:  2021-08-17

3.  Access to Telepharmacy Services May Reduce Hospital Admissions in Outpatient Populations During the COVID-19 Pandemic.

Authors:  Erik Hefti; Benjamin Wei; Kristen Engelen
Journal:  Telemed J E Health       Date:  2022-01-11       Impact factor: 5.033

4.  Effect of a pharmacist-led educational intervention on clinical outcomes: a randomised controlled study in patients with hypertension, type 2 diabetes and hypercholesterolaemia.

Authors:  Clement Delage; Hélène Lelong; Francoise Brion; Jacques Blacher
Journal:  Eur J Hosp Pharm       Date:  2021-06-28

5.  Incidence, types and acceptability of pharmaceutical interventions about drug related problems in a general hospital: an open prospective cohort.

Authors:  Valdjane Saldanha; Rand Randall Martins; Sara Iasmin Vieira Cunha Lima; Ivonete Batista de Araujo; Antonio Gouveia Oliveira
Journal:  BMJ Open       Date:  2020-04-23       Impact factor: 2.692

6.  Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission.

Authors:  Sarah Seiberth; Dominik Bauer; Ulf Schönermarck; Hanna Mannell; Christian Stief; Joerg Hasford; Dorothea Strobach
Journal:  Eur J Clin Pharmacol       Date:  2020-07-10       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.